Scarica l'app Stockscreener
0.8888
9.16%
-0.0896
Dopo l'orario di chiusura:
.91
0.0212
+2.39%
Precedente Chiudi:
$0.9784
Aprire:
$1.01
Volume 24 ore:
74,788
Relative Volume:
0.50
Capitalizzazione di mercato:
$22.49M
Reddito:
-
Utile/perdita netta:
$-39.22M
Rapporto P/E:
-0.501
EPS:
-1.7742
Flusso di cassa netto:
$-17.31M
1 W Prestazione:
-11.12%
1M Prestazione:
-16.15%
6M Prestazione:
+8.99%
1 anno Prestazione:
+64.32%
Intervallo 1D:
$0.87
$1.01
Intervallo di 1 settimana:
$0.87
$1.3295
Portata 52W:
$0.375
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Nome
AEON Biopharma Inc.
Settore
Industria
Telefono
(949) 354-6499
Indirizzo
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.8888 | 22.49M | 0 | -39.22M | -17.31M | -1.7742 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-18 | Iniziato | H.C. Wainwright | Buy |
AEON Biopharma Inc. Borsa (AEON) Ultime notizie
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - TipRanks
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma Received Notice of Noncompliance - TradingView
New AEON finance chief gets stock awards tied to NYSE compliance - Stock Titan
AEON Biopharma (NYSE American: AEON) faces added NYSE equity noncompliance risk - Stock Titan
AEON stays on NYSE despite $55 million deficit as deadline nears - Stock Titan
AEON Biopharma 2025 Financial Review - AlphaStreet
Stock Market Recap: Whats the profit margin of AEON Biopharma Inc - baoquankhu1.vn
AEON Biopharma reports biosimilar progress, secures financing By Investing.com - Investing.com Australia
AEON Forecast, Price Target & Analyst Ratings | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
Can AEON Biopharma Inc keep up with sector leaders2026 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
AEON Biopharma 2025 10-K: Net loss $39.2M, EPS $(3.95) - TradingView
AEON Biopharma (AEON) advances Botox biosimilar plan but warns on going concern - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
[8-K] AEON Biopharma, Inc. Reports Material Event - Stock Titan
AEON Biopharma reports biosimilar progress, secures financing - Investing.com
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - The Manila Times
AEON's Botox biosimilar matched 3,400 amino acids as FDA mapped next steps - Stock Titan
Latest AEON NewsAEON Biopharma Presents Positive Results fr... - Stock Titan
Biotech Landscape Update: Regulatory Approvals and Mergers - Intellectia AI
Aeon Biopharma announces FDA feedback after Type 2a meeting - Yahoo Finance
AEON Biopharma receives FDA feedback on botulinum toxin biosimilar - Investing.com
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program - The Manila Times
FDA maps next steps for AEON's bid to bring a Botox biosimilar - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Aeon Biopharma (AEON) - Stock Titan
AEON Biopharma, Inc.: Fundamental Analysis and Financial Ratings | AEON | US00775E1029 - marketscreener.com
Technical Analysis: Whats the profit margin of AEON Biopharma Inc2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Travel Stocks: How much upside does AEON Biopharma Inc haveQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Profit Recap: Can AEON Biopharma Inc stock outperform in a bear marketMarket Performance Report & Low Risk Entry Point Guides - baoquankhu1.vn
Risk Analysis: Is AEON Biopharma Inc stock good for income investors2026 Trade Ideas & Safe Entry Point Identification - baoquankhu1.vn
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (NASDAQ: AEON) CMO granted RSUs and modifies 1,316,872-unit award - Stock Titan
AEON Biopharma names John Bencich as chief financial officer - Investing.com Australia
AEON Biopharma Appoints John Bencich as Chief Financial Officer - The Manila Times
AEON Biopharma Strengthens Finance Leadership with New CFO - TipRanks
AEON Biopharma names John Bencich as chief financial officer By Investing.com - Investing.com Canada
AEON appoints John Bencich as CFO; Jennifer Sy employment terms confirmed - TradingView
New AEON Biopharma (NYSE: AEON) CFO hired as company expands inducement equity pool - Stock Titan
AEON Biopharma, Inc. Appoints John Bencich as Chief Financial Officer, Effective as of March 9, 2026 - marketscreener.com
How cyclical is AEON Biopharma Inc. Class stock compared to rivalsInflation Watch & AI Enhanced Trading Signals - Naître et grandir
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting - The Manila Times
AEON (AEON) CLO adds large stock awards and converts prior RSUs - Stock Titan
AEON Biopharma (AEON) details major stock unit grants to officer - Stock Titan
Botox biosimilar study from AEON Biopharma set for big U.S. neurology meeting - Stock Titan
AEON Biopharma Inc. Azioni (AEON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Capitalizzazione:
|
Volume (24 ore):